Avalyn Pharma Inc.
AVLNNasdaqCIK 1540171HealthcareFiscal year ends Dec 31
Reports and events: 13 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1616:13 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-393081 |
| 2026-08-1208:15 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-345820 |
| 2026-08-1208:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345807 |
| 2026-07-0117:20 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-292834 |
| 2026-06-1708:03 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-26-273405 |
| 2026-06-0308:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-254623 |
| 2026-06-0307:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-254581 |
| 2026-05-0818:52 ET | SCHEDULE 13D | Ownership report, active investor | 0000899140-26-000428 |
| 2026-05-0816:41 ET | SCHEDULE 13D | Ownership report, active investor | 0001072613-26-000386 |
| 2026-05-0116:09 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-201434 |
| 2026-04-2909:29 ET | S-1/A | Registration statement, amended | 0001193125-26-189477 |
| 2026-04-2316:01 ET | S-1/A | Registration statement, amended | 0001193125-26-173632 |
| 2026-04-0816:01 ET | S-1 | Registration statement | 0001193125-26-147573 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:13 ET. Listed shows no prices and gives no investment advice.